Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration

A macular degeneration and peroxide technology, applied in the direction of active ingredients of peroxide compounds, medical preparations of non-active ingredients, medical preparations containing active ingredients, etc., can solve problems such as danger

Inactive Publication Date: 2008-10-15
罗伯特·F·霍夫曼
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Therefore, they are very dangerous when formulated or stored

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration
  • Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration
  • Use of targeted oxidative therapeutic formulation in treatment of age-related macular degeneration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0073] Example 1: Ozonolysis of Unsaturated Hydrocarbons

[0074] The ozonolysis of olefins is carried out in solvent or neat. In both cases, cooling of the reaction mixture is critical in avoiding explosive decomposition of the peroxidic product of the reaction.

[0075] The following general procedure is typical for the ozonolysis of liquid olefins.

[0076] A 1 liter flask equipped with a magnetic stirrer was charged with olefin (2 moles) and the apparatus was weighed. The flask was placed in a cooling bath (ice-water or ice-salt). When the contents have cooled below 5°C, agitation is started and dry oxygen containing ozone (typically 3% ozone) is passed through the mixture. It is convenient to vent the ozone-containing oxygen through the glass frit, but this is not necessary for a solution that is being stirred. Gas flow is periodically interrupted for reaction vial weighing or reaction mixture sampling, after which gas flow is resumed.

[0077] When the weight of the...

Embodiment 2

[0080] Embodiment 2: the preparation of pharmaceutical preparation

[0081] The preferred pharmaceutical formulation of the present invention is prepared as follows:

[0082] (1) Ozone / pure oxygen gas mixture 120mg / L is bubbled through dienol, 3,7-dimethyl-2,6-octadien-1-ol (geraniol), 1 liter / hour;

[0083] (2) The reaction temperature is maintained at about 5°C;

[0084] (3) A small portion of the reaction product is taken out every 1 hour and passed through H 1 NMR to detect the formation of peroxides or reaction products;

[0085] (4) When there are more than 50% available unsaturated bond reactions, stop the reaction;

[0086] (5) Dilute the product mixture (1:10) with dimethyl sulfoxide to form a solution or dispersion;

[0087] (6) Before being applied to the target biological system, add a sufficient amount of dry powder mixture of hematoporphyrin, rose bengal and menaquinone to the solution or dispersion, and spread it in the target biological system when injected...

Embodiment 3

[0088] Embodiment 3: the example of pharmaceutical preparation

[0089] Two preferred formulations are as follows:

[0090] a.

[0091] weight%

[0092] *Detected by mass spectrometry

[0093] b.

[0094] weight%

[0095] *Detected by mass spectrometry

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a pharmaceutical formulation and use thereof. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethylsulfoxide (''DMSO''); a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to effectively treat patients affected with age-related macular degeneration (''ARMD'').

Description

[0001] related application [0002] This application claims the priority of U.S. Provisional Patent Application No. 60 / 569,554, the title of the provisional application is "Use of Targeted Oxidative Therapeutic Formulation in Treatment of Age-Related Macular Degeneration", the filing date is May 10, 2004, all of which The contents are hereby incorporated by reference. technical field [0003] The present invention relates to a composition containing peroxide or oxidation product and its preparation method and application. More specifically, the present invention relates to a pharmaceutical composition or formulation comprising: a peroxide or a reaction product obtained by oxidation of an olefinic compound (either in liquid form or in solution) with an oxygen-containing oxidizing agent such as ozone; penetrating solvents; dyes containing chelated metals; and aromatic redox compounds. The invention also relates to the preparation of the pharmaceutical preparation and its appli...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K47/18A61K47/10A61K47/22A61K31/045A61K31/10A61K31/12A61K31/327A61K31/353A61K31/409A61K31/555A61K31/695A61K45/06A61K47/20
CPCA61K47/10A61K9/0019A61K31/045A61K31/10A61K31/12A61K31/327A61K31/353A61K31/409A61K31/555A61K31/695A61K45/06A61K47/18A61K47/20A61K47/22A61K2300/00
Inventor 罗伯特·F·霍夫曼
Owner 罗伯特·F·霍夫曼
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap